ESR1 and breast carcinoma: In addition to its role in ER+ BCs, KDM5B contributes to BC progression in triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer defined by a lack of ER, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression81.